

Top 20: Singapore - High growth

09 July 2014 | Analysis | By BioSpectrum Bureau





Singapore: Singapore has been witnessing strong performance. Here are a few developments in the country that are proof to increasing its bioscience presence.

Alcon, global eye-care firm, launched an ophthalmic pharmaceutical manufacturing facility in Singapore with an investment of \$159.6 million to produce ophthalmic pharmaceutical products to address eye conditions such as glaucoma, dry eye, allergies and bacterial infections.

Thermo Fisher Scientific and National University of Singapore entered into a strategic alliance to advance basic and applied research in Singapore for future discoveries and development of applications.

Global generics firm, Actavis, opened its regional office in Singapore to serve as the headquarters for the company's Asia Pacific and Africa (APACA) region.

Singapore launched National Neuroscience Research Institute Singapore (NNRIS), a joint venture by the National Neuroscience Institute (NNI) and Duke-NUS Graduate.

Medical School to improve treatment and seek cure through research for brain and nervous system disorders such as stroke, Parkinson disease and dementia.

Scientists at A*Star's Genome Institute of Singapore (GIS) and US-based Stanford University's School of Medicine produced one of the first ever genome-wide views of Ribonucleic acid (RNA) shape patterns in humans paving way for scientists to better understand the basis of human mutations.

Japan and Singapore signed memorandum of understanding to accelerate the development and commercialization of innovative products such as drugs, diagnostic tests and medical devices to be approved for markets such as Japan, the US, the EU, and Asia targeting cancer, heart disease, Alzheimer's, diabetes and infectious diseases like dengue.

| Rank | Company | Revenue | | |
|------------------------------------|-------------------------------|------------------|------------------|---------------------|
| | | CY 2013 (\$M) | CY 2012 (\$M) | Change over 2012 |
| 1 | Sihuan Pharmaceutical Company | 734.2 | 462.9 | 59% |
| 2 | Zagro Asia | 106.1 | 98.6 | 8% |
| 3 | STAR Pharmaceutical | 13.7 | 13.4 | 3% |
| 4 | Scigen | 20.8 | 18.2 | 14% |
| * Revenue of listed companies only | | | | |